作者
Pierre-Antoine Laurent,Fabrice André,Alexandre Bobard,Désirèe Deandreis,Sandra Demaria,Stéphane Depil,Stefan B. Eichmüller,Cristian Fernández-Palomo,Floris Foijer,Lorenzo Galluzzi,Jérôme Galon,Matthias Gückenberger,Kevin J. Harrington,Fernanda G. Herrera,Peter Huber,A. Italiano,Sana D. Karam,Guido Kroemer,Philippe Lambin,Carola Leuschner,Alberto Mantovani,Etienne Meylan,Michele Mondini,Mikaël J. Pittet,Jean‐Pierre Pouget,Jordi Remón,Claus Storgaard Sørensen,Christos Sotiriou,Claire Vanpouille‐Box,Ralph R. Weichselbaum,James W. Welsh,Laurence Zitvogel,Silvia C. Formenti,Éric Deutsch
摘要
Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer. Herein, we report on the topics developed by key-opinion leaders during the 7